BVF PARTNERS L P/IL
CIK 1055947 · last filed 2025-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.12B
Companies
26
Total Filings
54
Lifetime Open-Market Net
$77.38M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 353,412 | $86.20 | $30.47M | $139.55M | 1 | 2025-07-01 |
| PVLA | 282,223 | $108.81 | $30.71M | $0 | 1 | 2024-12-17 | |
| MLTX | Director | 9,005,700 | $18.69 | $168.32M | $0 | 1 | 2024-06-10 |
| ELDN | 10%+ Owner | 3,361,803 | $3.57 | $12.00M | $0 | 1 | 2024-05-13 |
| XOMAP | Director | 1,556,696 | $25.46 | $39.64M | $0 | 1 | 2022-05-20 |
| RAIN | Director | 1,367,838 | $2.04 | $2.79M | $266.23M | 3 | 2022-01-10 |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 1,578,732 | $90.00 | $142.09M | -$290.16M | 3 | 2021-10-08 |
| OLMA | Director | 535,638 | $9.87 | $5.29M | $0 | 1 | 2021-05-26 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,279,831 | $0.04 | $146.6K | $1.47M | 2 | 2021-02-19 |
| CTMX | 358,450 | $3.01 | $1.08M | $0 | 1 | 2021-02-18 | |
| XOMA | 10%+ Owner | 2,194,410 | $41.79 | $91.70M | $1.20M | 1 | 2020-08-20 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 346,627 | $38.00 | $13.17M | $4.44M | 1 | 2019-10-25 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 2,734,725 | $9.09 | $24.86M | $8.53M | 2 | 2017-06-14 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | 10%+ Owner | 1,099,526 | — | — | $1.16M | 1 | 2017-06-07 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 3,298,293 | — | — | $5.57M | 2 | 2014-12-17 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 1,121,221 | — | — | $0 | 1 | 2014-03-25 | |
| PTN | 10%+ Owner | 438,127 | $13.61 | $5.96M | -$5.62M | 2 | 2014-03-03 |
| CCXI | 10%+ Owner | 2,079,532 | $10.22 | $21.25M | $10.51M | 3 | 2013-12-05 |
| LGND | 10%+ Owner | 16,219,812 | $255.54 | $4.14B | -$46.58M | 7 | 2013-01-25 |
| NBIX | 10%+ Owner | 6,658,212 | $159.76 | $1.06B | -$8.66M | 4 | 2012-02-10 |
| ICAGEN INC (ICGN) Delisted | 10%+ Owner | 219,700 | — | — | $4.56M | 1 | 2011-09-09 |
| CAPS | 10%+ Owner | 820,100 | $0.29 | $241.9K | $149.9K | 1 | 2011-06-29 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 18,772,784 | — | — | $8.96M | 1 | 2011-04-07 |
| RPRX | 10%+ Owner | 9,191,102 | $54.87 | $504.32M | -$4.03M | 1 | 2009-09-21 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 8,557,702 | $15.50 | $132.64M | -$20.11M | 1 | 2009-09-11 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,459,999 | — | — | $181.2K | 3 | 2008-12-05 |
Recent Filings · Page 2 of 6
54 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-02-19 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | — | — | $0 | EDGAR |
| 2021-02-18 | CTMX | — | — | $0 | EDGAR |
| 2020-08-20 | XOMA | Buy (P) | +61,630 | $1.20M | EDGAR |
| 2020-06-10 | Merus N.V. (MRUS) Delisted | Buy (P) | +872,540 | $13.26M | EDGAR |
| 2020-01-15 | Merus N.V. (MRUS) Delisted | Buy (P) | +587,734 | $8.80M | EDGAR |
| 2019-10-25 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +1,185,590 | $4.44M | EDGAR |
| 2018-12-17 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +1,225,000 | $1.47M | EDGAR |
| 2018-12-04 | — | Sell (S) | −6,314,000 | -$11.58M | |
| 2017-06-14 | CTI BIOPHARMA CORP (CTIC) Delisted | Mixed | +28,816,662 | $0 | EDGAR |
| 2017-06-07 | ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Buy (P) | +508,550 | $1.16M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.